share_log

Sailong Pharmaceutical GroupLtd's (SZSE:002898) Promising Earnings May Rest On Soft Foundations

Sailong Pharmaceutical GroupLtd's (SZSE:002898) Promising Earnings May Rest On Soft Foundations

赛隆药业集团有限公司(SZSE:002898)的盈利前景可能存在不稳定因素
Simply Wall St ·  09/04 18:13

Despite posting some strong earnings, the market for Sailong Pharmaceutical Group Co.,Ltd.'s (SZSE:002898) stock hasn't moved much. We did some digging, and we found some concerning factors in the details.

尽管公布了一些强劲的收益,但赛龙制药集团股份有限公司的市场依然表现良好, Ltd. 's (SZSE: 002898) 股票没有太大变动。我们进行了一些挖掘,在细节中发现了一些相关的因素。

big
SZSE:002898 Earnings and Revenue History September 4th 2024
SZSE: 002898 2024 年 9 月 4 日的收益和收入历史记录

The Impact Of Unusual Items On Profit

不寻常物品对利润的影响

To properly understand Sailong Pharmaceutical GroupLtd's profit results, we need to consider the CN¥9.3m gain attributed to unusual items. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's as you'd expect, given these boosts are described as 'unusual'. We can see that Sailong Pharmaceutical GroupLtd's positive unusual items were quite significant relative to its profit in the year to June 2024. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

为了正确理解赛龙制药集团有限公司的盈利业绩,我们需要考虑归因于不寻常项目的930万元人民币的收益。虽然我们希望看到利润增加,但当不寻常的物品做出重大贡献时,我们往往会更加谨慎一些。当我们分析全球绝大多数上市公司时,我们发现重大不寻常的事项往往不会重演。这正如你所预料的那样,因为这些增强被描述为 “不寻常”。我们可以看到,相对于截至2024年6月的一年中,赛龙制药集团有限公司的正面不寻常项目与其利润相比相当可观。在其他条件相同的情况下,这可能会使法定利润成为衡量潜在盈利能力的不良指导。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Sailong Pharmaceutical GroupLtd.

注意:我们始终建议投资者检查资产负债表的实力。点击此处查看我们对赛龙制药集团有限公司的资产负债表分析。

Our Take On Sailong Pharmaceutical GroupLtd's Profit Performance

我们对赛龙药业集团有限公司盈利表现的看法

As previously mentioned, Sailong Pharmaceutical GroupLtd's large boost from unusual items won't be there indefinitely, so its statutory earnings are probably a poor guide to its underlying profitability. For this reason, we think that Sailong Pharmaceutical GroupLtd's statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. The good news is that it earned a profit in the last twelve months, despite its previous loss. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. If you want to do dive deeper into Sailong Pharmaceutical GroupLtd, you'd also look into what risks it is currently facing. When we did our research, we found 3 warning signs for Sailong Pharmaceutical GroupLtd (1 is a bit concerning!) that we believe deserve your full attention.

如前所述,赛龙制药集团有限公司不会无限期地从不寻常项目中获得巨额提振,因此其法定收益可能无法指导其潜在盈利能力。出于这个原因,我们认为赛龙制药集团有限公司的法定利润可能不利于其潜在盈利能力,并可能给投资者留下过于积极的公司印象。好消息是,尽管之前出现亏损,但它在过去十二个月中还是实现了盈利。本文的目标是评估我们在多大程度上可以依靠法定收益来反映公司的潜力,但还有很多需要考虑的地方。如果你想更深入地了解赛龙制药集团有限公司,你还需要研究它目前面临的风险。当我们进行研究时,我们发现了赛龙制药集团有限公司的3个警告信号(1个有点令人担忧!)我们认为值得你全神贯注。

Today we've zoomed in on a single data point to better understand the nature of Sailong Pharmaceutical GroupLtd's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

今天,我们放大了单一数据点,以更好地了解赛龙制药集团有限公司利润的性质。但是,还有很多其他方法可以让你对公司的看法。例如,许多人认为高股本回报率是有利的商业经济的标志,而另一些人则喜欢 “关注资金”,寻找内部人士正在买入的股票。虽然可能需要你进行一些研究,但你可能会发现这份免费收集的拥有高股本回报率的公司,或者这份拥有大量内幕持股的股票清单很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧吗?请直接联系我们。或者,也可以发送电子邮件至编辑团队 (at) simplywallst.com。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发